AI Consensus Investment Thesis
SOON: Sonova H Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Sonova H: 1-Year and 5-Year Forecast Outlook and Rating
Sonova H (SOON) has an immediate No Action - Keep Monitoring consensus AI recommendation, based on 14 AI analysts.
The 1-year target is 247 CHF for , with -11.34% expected return (-10.46% including net dividends) and a SELL ALL rating.
The 5-year target is 333 CHF for , with +19.53% expected return (+26.10% including net dividends) and a NEUTRAL rating.
Latest available market price: CHF 279, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 1.1%. As of 2026-10-20.
Gross TTM: 1.69% · Two-year annualized gross: 1.63%.
Tax withholding assumption: 35% (CH). One-off special payments are excluded.
Original published assumption: 1.1% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Sonova H Flagship Insight
Acoustic Silicon Edge Clashes With Currency Drag and Channel Shifts
Consensus reveals high consensus on clinical acoustic silicon leadership and demographic tailwinds, counterbalanced by sharp divergence regarding valuation multiples and retail distributor consolidation. While proprietary AI processing and consumer hearing divestment expand core margins, relentless Swiss franc translation drag and wholesale channel risks constrain unhedged equity appreciation.
How were the Investment Thesis and Forecasts created?
14 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
J.P. Morgan (Titan)
Superintelligence (Anthropologist)
Machiavelli (Insider)
Michael Burry (Vulture)
Universal Investor (Polymath)
Ray Dalio (Strategist)
Elon Musk (Visionary)
Sherlock Holmes (Whistleblower)
Warren Buffett (Value Purist)
Ran across these frontier AI models
Google Gemini 3.8 Flash
Anthropic Claude Opus 5
OpenAI GPT-6 Astra
Latest published deep-analysis batch. Audit published forecasts in full transparency
Sonova H: forecast questions
What is Sonova H (SOON)'s 1-year price forecast?
Sonova H's 1-year target is 247 CHF for Sept 2027. The current AI rating is SELL ALL. The expected return from the recorded close is -11.34%, or -10.46% modeled return including net dividends. Latest available market price: CHF 279, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is Sonova H (SOON)'s 5-year price forecast?
Sonova H's 5-year target is 333 CHF for Sept 2031. The current AI rating is NEUTRAL. The expected return from the recorded close is +19.53%, or +26.10% modeled return including net dividends. Latest available market price: CHF 279, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is the return basis?
Latest available market price: CHF 279, as of 20 Oct 2026. These are model projections, not guaranteed future prices.
How can I compare the AI opinions and audit past Sonova H forecasts?
14 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History preserves earlier published batches; their figures describe their original publication, not today's outlook.
How does an AI-generated forecast for Sonova H differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Sonova H is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
Sonova H: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest CHF 10,000 in Sonova H at the latest market close (20 Oct 2026): CHF 12,610 by Sept 2031.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
Benchmark comparison requires matching dated price and currency inputs.
* Return is calculated incl. 1.1% net dividend yield for Sonova H.
Sonova presents a high-quality audiological compounding thesis where operational acceleration is partially sterilized by structural currency translation and distributor realignments. The base-case economic argument centers on proprietary real-time neural network silicon (Infinio and EON platforms) preserving premium wholesale average selling prices, while shedding the dilutive Sennheiser consumer hearing business purifies operating margins toward 21.5% to 22.5%. Valuation is sensitive to denominator corrections: screened multiples of fifteen times earnings are arithmetic illusions stemming from semi-annual reporting, whereas true normalized continuing earnings trade near twenty-two times, leaving modest room for multiple expansion.
Key insights
- Vertical integration of the owned AudioNova clinic network secures captive patient volume, insulating consolidated gross margins from distributor procurement pressure.
- Amplifon's acquisition of GN Hearing creates structural wholesale shelf displacement risks, forcing increased reliance on independent dispensers and institutional tenders.
- Persistent safe-haven Swiss franc strength permanently diverts constant-currency operational momentum, requiring continuous manufacturing automation and retail productivity gains.
Sonova H: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of CHF 279, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 1.1%. As of 2026-10-20.
Gross TTM: 1.69% · Two-year annualized gross: 1.63%.
Tax withholding assumption: 35% (CH). One-off special payments are excluded.
Original published assumption: 1.1% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 14 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 18 Sept 2026 at CHF 232. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD; FX values are exchange rates.
Scroll the table horizontally to read every column.
| Quarter | Evidence-Weighted Consensus Price Path | Individual Advisor Range & Reference Forecasts | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Consensus target (CHF) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (CHF) | Optimistic Advisor Base Case (CHF) | S&P 500 benchmark (USD) | FX (USD/CHF) | |
| CHF 233 | +0.32% | -16.37% | -16.22% | Phonak EON wholesale shipments accelerate across independent dispensing channels, but initial platform rollout expenditures and persistent Swiss franc translation drag temper reported earnings, producing a measured, range-bound share price reaction. | CHF 223 | CHF 241 | $750 | 0.84 | |
| CHF 237 | +1.84% | -14.93% | -14.55% | Audiologist re-orders confirm solid clinical adoption of proprietary acoustic silicon. Progress toward finalizing the Consumer Hearing divestiture reassures institutional investors, supporting steady organic growth and modest equity appreciation. | CHF 216 | CHF 249 | $736 | 0.84 | |
| CHF 246 | +3.68% | -11.70% | -11.06% | Full-year fiscal 2026/27 reporting delivers upper-guidance constant-currency revenue expansion. Excision of consumer audio operating drag combined with an increased annual dividend payment triggers positive sell-side earnings revisions. | CHF 212 | CHF 261 | $743 | 0.84 | |
| CHF 247 | +0.49% | -11.34% | -10.46% | Seasonal summer volume moderation and ongoing Swiss franc currency strength against major trading currencies restrain reported figures, while early distributor channel shifts following retail consolidation induce investor caution. | CHF 207 | CHF 266 | $755 | 0.84 | |
| CHF 253 | +2.44% | -9.19% | -8.03% | First-half fiscal 2027/28 results demonstrate core operating margin expansion as high-margin neural platform devices dominate mix. Captive clinic foot traffic provides defensive ballast against broader macroeconomic deceleration. | CHF 201 | CHF 277 | $776 | 0.84 | |
| CHF 258 | +2.18% | -7.39% | -5.96% | Mid-tier adoption of real-time AI algorithms expands across commercial networks. Disciplined working capital management and cash proceeds from portfolio pruning reinforce the balance sheet, enabling steady per-share value compounding. | CHF 205 | CHF 285 | $787 | 0.83 | |
| CHF 266 | +2.96% | -4.52% | -2.78% | Audited annual figures validate core EBITA margin expansion above twenty-one percent. Operating leverage from owned retail clinics offsets European public procurement pricing caps, driving sustained institutional accumulation. | CHF 209 | CHF 297 | $803 | 0.83 | |
| CHF 269 | +1.18% | -3.45% | -1.41% | Competitive platform counter-launches by Nordic rivals introduce selective commercial discounting. Sonova protects premium wholesale price realization, keeping gross margins above seventy-three percent while share prices consolidate. | CHF 203 | CHF 302 | $812 | 0.82 | |
| CHF 276 | +2.53% | -0.93% | +1.43% | Next-generation platform upgrades and strong replacement cycles across North American private audiology practices support volume acceleration. Easing global policy interest rates provides modest valuation support across European medtech. | CHF 205 | CHF 312 | $839 | 0.82 | |
| CHF 281 | +1.75% | +0.86% | +3.55% | Targeted expansion of AudioNova retail clinics across high-growth international hubs yields incremental volume. Direct fitting revenues buffer wholesale operations against periodic distributor inventory destocking into fiscal year-end. | CHF 209 | CHF 318 | $851 | 0.81 | |
| CHF 290 | +3.11% | +4.09% | +7.16% | Annual financial results confirm dependable free cash conversion above eighty-five percent. Modest debt deleveraging and progressive dividend distributions reward patient capital, prompting measured equity appreciation. | CHF 213 | CHF 330 | $872 | 0.81 | |
| CHF 290 | +0.12% | +4.09% | +7.45% | Consumer technology encroachment into mild-loss hearing assistance prompts heightened retail marketing expenditures. Defensive replacement demand for severe clinical indications maintains overall volume stability, limiting valuation multiple movement. | CHF 209 | CHF 334 | $886 | 0.81 | |
| CHF 297 | +2.32% | +6.60% | +10.35% | Interim financial results highlight solid organic growth in custom in-the-ear instruments. Clinic workflow automation improves audiologist productivity, neutralizing wage inflation and supporting healthy store-level operating margins. | CHF 205 | CHF 344 | $910 | 0.81 | |
| CHF 302 | +1.75% | +8.40% | +12.50% | Demographic expansion across aging Western populations provides continuous replacement volume. Sonova's asset-light manufacturing model preserves high return on invested capital, enabling steady per-share intrinsic value accumulation. | CHF 209 | CHF 351 | $916 | 0.80 | |
| CHF 310 | +2.75% | +11.27% | +15.80% | Full-year fiscal 2029/30 results highlight operating income crossing nine hundred million francs. Management increases shareholder capital returns through active buybacks, reinforcing market confidence in long-term earnings durability. | CHF 215 | CHF 361 | $937 | 0.80 | |
| CHF 313 | +0.82% | +12.35% | +17.24% | A mature industry backdrop and stable market shares lead to low-volatility summer trading. Captive retail dispensary cash flows insulate corporate profitability from broader macroeconomic and currency fluctuations. | CHF 209 | CHF 368 | $947 | 0.80 | |
| CHF 319 | +1.94% | +14.50% | +19.82% | Commercial rollout of updated diagnostic features and bimodal cochlear connectivity generates solid second-half orders. High patient switching costs defend the wholesale franchise against low-cost commercial alternatives. | CHF 205 | CHF 379 | $970 | 0.79 | |
| CHF 324 | +1.47% | +16.30% | +22.02% | Pre-fiscal-year-end procurement volumes in institutional channels confirm sustained clinical preference. Favorable cash flow conversion maintains fortress solvency, supporting ongoing bolt-on clinic acquisitions without debt strain. | CHF 207 | CHF 387 | $980 | 0.79 | |
| CHF 331 | +2.24% | +18.81% | +25.00% | Fiscal 2030/31 financial reporting confirms delivery of normalized operating margins near twenty-two percent. Solid operational execution completes the five-year strategic cycle, driving final valuation alignment with mature medtech compounders. | CHF 202 | CHF 399 | $1,000 | 0.79 | |
| CHF 333 | +0.74% | +19.53% | +26.10% | Shares consolidate gains as the enterprise establishes a dependable cash-generative equilibrium. Enduring clinical moats and consistent capital distributions anchor terminal equity valuation at a sustainable quality premium. | CHF 205 | CHF 403 | $1,012 | 0.79 | |
Show remaining 18 quartersShow first 2 quarters only
All 20 quarters are displayed in the table above.
Sonova H Stock Analysis & Scenarios Deep Dive
Sonova H: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? Prevailing market sentiment views the company as a low-growth medtech incumbent trapped by a relentlessly strong Swiss franc and stagnant top-line revenue. Sell-side commentary assumes consumer hearables and retail distributor consolidation will permanently compress margins, while unadjusted databases publish misleadingly low trailing valuation multiples that mask the true cost of the equity.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates core earnings power by mistaking reported Swiss franc optical drag for operational stagnation. In local currencies, wholesale volumes are expanding at mid-single digits driven by real-time neural acoustic silicon, while excising consumer audio terminates chronic operating losses. However, the market also overlooks that the true valuation multiple is above twenty-two times normalized earnings rather than fifteen times, meaning returns will be driven by operational cash flow compounding rather than multiple expansion.
Repricing Catalyst
What could make the market recognize and close that gap? Semi-annual financial releases and commercial order audits for the new neural platform represent the primary repricing catalyst. Demonstrating organic wholesale volume acceleration alongside gross margin defense above 73% will prove that clinical pricing power remains uncompromised. Finalizing the consumer hearing divestiture by 2027 will confirm operating margin expansion, forcing sell-side analysts to upgrade normalized cash flow models.
Sonova H: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Balanced
- Volatility Regime
- Moderate
- Convergence Cycle Position
- Stabilization
Sentiment is balanced between recognition of real-time AI product superiority and apprehension over distributor vertical integration and currency translation. Disagreement centers on whether current valuation offers a deep discount or fully prices in moderate long-term growth.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic backdrop of elevated global policy rates and safe-haven capital flows generates a mixed setup. High discount rates penalize premium medical technology multiples, and persistent Swiss franc strength acts as a chronic translation drag on foreign earnings. Conversely, medically non-discretionary patient demand and high gross margins insulate corporate cash flows from discretionary consumer spending retrenchment.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary analytical disagreement concerns valuation interpretation and distributor disruption severity. One perspective argues Sonova trades at an extreme discount near fifteen times earnings, but this stems from an unadjusted semi-annual reporting artifact. Audited continuing operations establish that true normalized earnings trade near twenty-two times, tempering expectations of rapid multiple expansion. A second debate centers on Amplifon's acquisition of GN Hearing: cautious views anticipate severe wholesale volume foreclosure, whereas optimistic perspectives argue clinician preference and proprietary acoustic AI silicon will preserve independent dispensing share. Monitoring wholesale order volumes will resolve these debates.
Sonova H: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Proprietary real-time neural acoustic processing | Innovation And Product | +20% | +24% | Deployment of dedicated deep neural network silicon across Phonak platforms solves speech-in-noise intelligibility, the primary complaint in hearing rehabilitation. Dedicated hardware achieves real-time sound separation at microwatt power envelopes, driving wholesale market share gains and protecting premium average selling prices above seventy-three percent gross margin. |
| Global demographic presbycusis volume expansion | Sector And Industry | +16% | +20% | Accelerating civilizational aging across major markets provides an expanding, non-cyclical patient base. Because prescription hearing aid adoption remains below forty percent in developed nations, secular volume expands reliably by four to six percent annually, supporting high manufacturing capacity utilization and steady cash generation. |
| Consumer hearing divestment portfolio purification | Capital Allocation | +14% | +16% | Divesting the dilutive Sennheiser consumer hearing segment eliminates chronic operating losses, inventory volatility, and promotional discounting. Reallocating freed capital into core medical audiology research and captive retail clinics structurally elevates consolidated operating margins and enhances return on invested capital. |
| Captive audiological retail network integration | Competitive Positioning | +12% | +14% | Expanding the AudioNova direct retail network across thousands of clinics captures both wholesale manufacturing margins and lucrative retail fitting fees. Direct clinic ownership insulates the group against wholesale distributor consolidation, locks in patient lifetime care, and preserves pricing power against lower-cost alternatives. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Persistent Swiss franc currency translation drag | Macroeconomic And Macrofinancial | -13% | -15% | Generating over eighty-five percent of group revenue abroad while maintaining substantial corporate, research, and manufacturing expenses in hard Swiss francs creates a chronic translation penalty. Ongoing safe-haven franc appreciation regularly erases four to six percentage points of reported growth, dampening reported earnings. |
| Distributor vertical integration channel displacement | Competitive Positioning | -11% | -12% | Amplifon's acquisition of GN Hearing converts a major wholesale customer into a vertically integrated competitor across thousands of clinics. Progressive shelf-space reallocations toward internal brands risk displacing Sonova wholesale volume, compressing wholesale operating leverage and requiring aggressive retail defense. |
| Public healthcare reimbursement tariff austerity | Regulatory | -9.0% | -10% | Fiscal strain across European national health authorities and US government programs drives competitive procurement bidding and tender price ceilings. Strict reimbursement caps across public healthcare channels restrict Sonova's ability to pass through inflationary costs, tightening gross margins across tender-dependent wholesale lines. |
| Audiological retail clinic wage inflation | Operational Efficiency | -8.0% | -9.0% | Operating extensive physical retail clinic networks exposes Sonova to skilled audiological labor shortages and sticky lease commitments across North America and Europe. Rising clinical salaries and retail overhead inflate selling expenses, dampening the operating leverage delivered by wholesale product launches. |
Sonova H: What Could Break or Accelerate the Thesis
Event Risk Score: Very Low 16/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Consumer electronics clinical hearing disruption | 28% | -25% | Mass-market wireless earbuds achieving certified clinical-grade speech separation under over-the-counter regulatory frameworks could cannibalize mild-to-moderate hearing loss demand. Bypassing traditional audiology dispensaries would erode entry-level clinic foot traffic, compressing wholesale pricing and threatening retail dispensary capital investments. |
| Severe cochlear implant clinical recall | 18% | -22% | A systemic hermetic seal or biomaterial defect within the Advanced Bionics surgical implant portfolio triggering mandatory global regulatory recalls would severely damage clinical reputation. Beyond direct warranty provisions and litigation damages, hospital surgical centers would migrate implant allocations entirely to entrenched competitors. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| US Medicare statutory hearing coverage mandate | 25% | +28% | Federal legislative reform establishing comprehensive hearing aid coverage under US Medicare Part B would remove the primary financial barrier for tens of millions of seniors. This policy shift would spark an immediate volume surge across commercial audiology, unlocking substantial wholesale demand and expanding corporate valuation multiples. |
| Major US retail private-label partnership renewal | 32% | +22% | Negotiating a high-volume private-label manufacturing partnership with a major US warehouse club would instantly re-establish massive retail volume. Accessing high-throughput commercial dispensary channels would accelerate production scale economies, optimize factory utilization, and add hundreds of millions in high-margin wholesale revenue. |
Company Financial AnalysisSonova H: Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included. View latest Sonova H financials here.
Earnings and financials
Sonova presents two contrasting financial realities. In reported Swiss francs, revenue has appeared stagnant around CHF 3.61 billion due to sharp currency translation penalties. However, underlying sales in local currencies grew 5.9% in fiscal 2025/26, driven by solid volume gains in prescription hearing aids. Reported net income declined to CHF 431 million after restructuring charges and losses from the consumer hearing business. Crucially, underlying cash generation remained robust, producing over CHF 600 million in free cash flow, proving that the core medical franchise remains healthy.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2026 | CHF 3.6B | CHF 430.6M | CHF 602.7M |
| 2025 | CHF 3.6B | CHF 540.5M | CHF 656.1M |
| 2024 | CHF 3.6B | CHF 601M | CHF 624.7M |
| 2023 | CHF 3.7B | CHF 647.5M | CHF 609.1M |
| 2022 | CHF 3.4B | CHF 649M | CHF 815.9M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2026 | 11.9x | TTM | Native | CHF / CHF |
| 2025 | 15.7x | TTM | Native | CHF / CHF |
| 2024 | 13.9x | TTM | Native | CHF / CHF |
| 2023 | 24.8x | Annual | Native | CHF / CHF |
| 2022 | 37.5x | Annual | Native | CHF / CHF |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Gross profit margins remained exceptional at 73.7% in fiscal 2025/26, demonstrating strong pricing power for advanced audiological hardware. The company easily defends premium device prices because patients and clinicians prioritize clinical hearing performance over cost. Reported operating margins dipped to 18.7% due to consumer headphone losses, clinic wage inflation, and foreign exchange friction. Exiting the consumer headphone business removes a persistent drain, positioning core operating margins to recover back toward 21% to 22% over time.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2026 | CHF 675.8M | 18.7% | 11.9% |
| 2025 | CHF 719.8M | 19.9% | 15.0% |
| 2024 | CHF 669.9M | 18.5% | 16.6% |
| 2023 | CHF 746.7M | 20.0% | 17.3% |
| 2022 | CHF 785.1M | 23.3% | 19.3% |
Balance sheet and leverage
Sonova maintains a fortress balance sheet characterized by low leverage and strong debt servicing capacity. Net debt closed fiscal 2025/26 near CHF 994 million, representing a very manageable 1.1 times EBITDA, while interest coverage stands at a resilient 24.6 times. While headline liquidity is solid with a current ratio of 1.75, investors must recognize that substantial balance-sheet assets consist of goodwill from past clinic acquisitions. Nonetheless, manageable debt maturities give management ample flexibility to self-fund strategic growth without issuing shares.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2026 | CHF 1.7B | CHF 722.1M | CHF 989.7M net debt | CHF 989.6M | 1.75x |
| 2025 | CHF 1.8B | CHF 687.1M | CHF 1.1B net debt | CHF 1.1B | 1.27x |
| 2024 | CHF 1.8B | CHF 513.8M | CHF 1.3B net debt | CHF 1.3B | 1.45x |
| 2023 | CHF 1.8B | CHF 414.8M | CHF 1.4B net debt | CHF 1.4B | 1.37x |
| 2022 | CHF 1.5B | CHF 612M | CHF 873.8M net debt | CHF 872.3M | 1.10x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
Management has maintained disciplined capital spending, reducing physical capital expenditures to 2.26% of revenue in fiscal 2025/26. Instead of building expensive factories, the company relies on flexible microelectronics partnerships, keeping physical maintenance costs exceptionally low. Capital is concentrated in research and development, which held steady at CHF 234 million to develop proprietary AI acoustic processors. This capital-light approach frees substantial cash to fund selective clinic acquisitions and progressive shareholder dividends.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2026 | CHF 81.4M | CHF 234.5M |
| 2025 | CHF 137.6M | CHF 233M |
| 2024 | CHF 128.6M | CHF 261M |
| 2023 | CHF 154.3M | CHF 271M |
| 2022 | CHF 106.6M | CHF 230.5M |
Behind the synthesisSonova H: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 14 advisor opinions. The weights and rationales below are retained from that synthesis.
The synthesized consensus balances robust operational compounding against rigorous accounting reality. A major pattern across several reports is anchoring to screen-based trailing multiples near fifteen times earnings, an illusion caused by unadjusted semi-annual reporting. Independent scrutiny confirms that audited continuing earnings reflect a price-to-earnings multiple above twenty-two times normalized and over thirty times reported net income. The strongest reports correctly adjust for this reality while evaluating the competitive disruption from Amplifon acquiring GN Hearing and persistent Swiss franc translation drag. Contrarian warnings regarding over-the-counter earbuds and channel displacement are credible at the entry level, but fail to overturn the non-discretionary nature of severe hearing impairment. Consequently, higher relative weights are awarded to reports that reject erroneous trailing multiples, incorporate structural foreign exchange headwinds, and ground valuation in audited cash flows rather than unverified multiple expansion.
All 14 opinions
Universal Investor AI
The Polymath
OpenAI GPT-6 Astra · 2026-09-03 releaseWeight: 15.7%
Demonstrates superior forensic discipline by auditing continuing operations, rejecting erroneous trailing multiples, and incorporating competitive AI launches like Oticon Reveal. The cautious valuation framing matches realistic five-year balance sheet and cash conversion dynamics without relying on multiple expansion.
Universal Investor AI
The Polymath
Anthropic Claude Opus 5 · 2026-07-24 releaseWeight: 15.7%
Exceptional analytical rigor exposing the semi-annual reporting denominator distortion that creates a false low price-to-earnings perception. Thoroughly models Amplifon distributor in-sourcing risks, realistic mid-single-digit franc earnings progression, and structural valuation sensitivity against higher bond yields.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.8%
Provides sound technical insight on proprietary acoustic silicon and consumer hearing divestment dynamics. However, it relies heavily on unadjusted local-currency operating metrics while downplaying persistent Swiss franc currency translation drag and wholesale channel risks.
Elon Musk AI
The Visionary
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.8%
Correctly emphasizes distributor foreclosure risks following Amplifon's acquisition of GN Hearing alongside entry-level hearable encroachment. However, its initial forecast path projects excessive multiple compression that underestimates audiological switching costs and captive clinic support.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.9%
Accurately captures demographic demand certainty, capital-light manufacturing, and high gross margin durability. Nevertheless, it exhibits correlated bullishness, failing to adjust for the actual reported earnings multiple and overestimating the speed of valuation re-rating.
Niccolo Machiavelli AI
The Insider
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.9%
Captures institutional procurement dynamics across the US Veterans Affairs channel and European reimbursement programs. It thoughtfully details AudioNova clinic rollups, though its terminal multiple assumptions remain somewhat generous given sovereign healthcare budget caps.
Michael Burry AI
The Vulture
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.9%
Offers valuable contrarian analysis regarding clinician brand loyalty despite Amplifon's consolidation. However, it relies on a flawed trailing multiple of fifteen times earnings, leading to an overly aggressive equity price target.
Ray Dalio AI
The Strategist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.9%
Delivers coherent macro-regime analysis regarding debt cycles, inflation, and healthcare non-discretionary demand. However, the path assumes an aggressive re-rating toward twenty-five times normalized earnings that conflicts with audited Swiss-franc cash flow leakages.
Sherlock Holmes AI
The Whistleblower
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.9%
Effectively isolates margin accretion from shedding consumer headphones, yet perpetuates the erroneous screened multiple claim. Its reliance on aggressive wholesale share conquest overlooks Danish competitor responses and tender bidding constraints.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.9%
Provides solid operational coverage of post-launch margin normalization following peak platform commercialization expenses. However, its valuation argument relies on multiple re-rating without adequately resolving the structural drag of Swiss franc appreciation on reported returns.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.9%
Correctly identifies edge-AI acoustic silicon leadership and clinical barriers to entry. However, it repeats uncritical acceptance of management's long-range targets, generating an overly optimistic compound trajectory that understates retail wage inflation.
J.P. Morgan AI
The Titan
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 3.9%
Clearly frames downstream clinical distribution rails and institutional tender moats. Its primary limitation is excessive optimism regarding the long-term revenue ambition, assuming double-digit multiple expansion while underplaying European tender price compression.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 3.9%
Offers an articulate view of economic moats and free cash conversion. Nevertheless, it accepts flawed database multiples claiming a deep discount, overestimating the margin of safety and projecting an unrealistically steep equity appreciation path.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 2.9%
Presents a rigorous contrarian warning regarding four-year top-line stagnation and hearable competition. However, its terminal multiple derating to sixteen times excessively discounts captive audiology clinic moats and inelastic severe-loss replacement cycles.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v7 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Sonova H forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher web32 available sources from this batch (67 recorded). The first 15 are shown below; expand to read the rest.
- FDA Authorizes First Over-the-Counter Hearing Aid Software | FDA fda.gov
- Sonova presents renewed strategy to expand market leadership with ambition to reach CHF 6 billion in revenue by FY 2030/31 - Sonova International sonova.com
- Sonova Holding AG stock (CH0012549785): UBS trims target as hearing aid demand stays in focus ad-hoc-news.de
- Sonova Holding AG Stock Unveils Bold CHF 6 Billion Revenue Strategy Amid Consumer Hearing Divestment ad-hoc-news.de
- Sonova stock holds its 2026 gains as new hearing-aid chip rolls out ad-hoc-news.de
- Sonova stock holds steady as 2026 dividend and sales targets stand out ad-hoc-news.de
- Sonova drops 8% as FY26 growth hits guidance low end, targets CHF 6 bln by 2031 By Investing.com au.investing.com
- Sennheiser is sold: Sonova divests itself of the headphone brand - Basic Tutorials basic-tutorials.com
- Sonova en.wikipedia.org
- Sonova Holding AG (SONVF) H2 25/26 earnings call transcript finance.yahoo.com
- Hearing Aids Market Size, Share, Trends, Growth Report [2034] fortunebusinessinsights.com
- Sennheiser is for sale: Sonova wants to divest itself of the headphone brand - Scholarly Articles, News, and Other Resources - Hearing Aid Forum - Active Hearing Loss Community forum.hearingtracker.com
- Sonova Plans to Sell Consumer Hearing Division as Part of New Long-Term Growth Strategy | Hearing Health & Technology Matters hearinghealthmatters.org
- Sonova Reports Strong FY 2025/26 Growth, Led by Infinio Platform hearingtracker.com
- Sonova drops 8% as FY26 growth hits guidance low end, targets CHF 6 bln by 2031 By Investing.com investing.com
Show 17 more sources
- Hearing aid manufacturers slide following Cochlear profit warning | MarketScreener marketscreener.com
- Hearing Aids Market Size & Forecast Report | Industry Trends 2031 mordorintelligence.com
- Introducing Oticon Reveal™ – the world’s first hearing aid powered by a Dual AI system oticon.com
- 3. Operating assets and liabilities - Sonova Annual Report 2025/26 report.sonova.com
- Balance sheets - Sonova Annual Report 2025/26 report.sonova.com
- Financial Review - Sonova Annual Report 2025/26 report.sonova.com
- Income statements - Sonova Annual Report 2025/26 report.sonova.com
- Letter to Shareholders - Sonova Annual Report 2025/26 report.sonova.com
- simplywall.st simplywall.st
- 1/4 Sonova Holding AG Laubisrütistrasse 28 8712 Stäfa Switzerland sonova.com
- Investors - Sonova International sonova.com
- Our Strategy - Sonova International sonova.com
- Sonova delivers strong FY 2025/26 results with continued ... sonova.com
- Sonova delivers strong FY 2025/26 results with continued market outperformance and increased profitability | Sonova International sonova.com
- Sonova delivers strong FY 2025/26 results with continued market outperformance and increased profitability - Sonova International sonova.com
- Sonova strengthens innovation leadership with Phonak EON portfolio and third-generation proprietary real-time AI - Sonova International sonova.com
- Sonova Holding AG: Target Price Consensus and Analysts Recommendations | SOON | CH0012549785 | MarketScreener UK uk.marketscreener.com
35 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
Archived context covering 2025-01-01 to 2025-12-31. Its recorded scope includes technology and capital cycle; trade and industrial policy; monetary policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 90.8K bytes
- Words
- 13.3K words
- Characters
- 90.8K characters
- Est. tokens (characters ÷ 4)
- 22.7K tokens
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Archived context covering 2026-01-01 to 2026-09-20. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 84.8K bytes
- Words
- 12.4K words
- Characters
- 84.8K characters
- Est. tokens (characters ÷ 4)
- 21.2K tokens
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2015-03-31–2026-03-31, 12 periods; Quarterly fiscal periods: 2023-09-30–2026-03-31, 6 periods.
Currencies cited: CHF, USD (quote CHF; primary reporting CHF; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.